<![CDATA[ASH22-Program for fremlæggelse af data på Genmabs lægemidler]]>Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 3, 2022 at 2:01 PM CET

Media Release

Copenhagen, Denmark, November 3, 2022

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies
Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome
New data evaluating investigational medicines in Genmab's early portfolio of cancer immunotherapies will also be presented
Genmab to host 2022 R&D Update and ASH Data Review meeting December 12

Se hele programmet for Genmab/ASH:

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual

]]>https://dev.proinvestor.com/forum/topic/444572/ash22-program-for-fremlggelse-af-data-p-genmabs-lgemidlerRSS for NodeSun, 28 Jun 2026 04:12:19 GMTSun, 11 Dec 2022 09:48:48 GMT60<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Tue, 13 Dec 2022 04:22:27 GMT]]>2022 R&D Update and ASH Data Review Dec 12, 2022 at 8:00 PM EST Genmab hosted its 2022 R&D Update and ASH Data Review on Monday, December 12, 2022.

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/9479620https://dev.proinvestor.com/forum/post/9479620Tue, 13 Dec 2022 04:22:27 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Mon, 12 Dec 2022 15:12:52 GMT]]>Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Link Preview Image
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

favicon

(www.prnewswire.com)

]]>https://dev.proinvestor.com/forum/post/9479621https://dev.proinvestor.com/forum/post/9479621Mon, 12 Dec 2022 15:12:52 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Mon, 12 Dec 2022 12:34:41 GMT]]>Genmab to Hold 2022 R&D Update and ASH Data Review Meeting https://www.proinvestor.com/investornyt

]]>https://dev.proinvestor.com/forum/post/9479618https://dev.proinvestor.com/forum/post/9479618Mon, 12 Dec 2022 12:34:41 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Mon, 12 Dec 2022 11:44:22 GMT]]>Genmab har netop præsenteret stærke data på Annual Meeting and Exposition of the American Society of Hematology (ASH). Hør mere i denne video med Helge Larsen.

Disclaimer: Dette er ikke en anbefaling om køb eller salg af aktien. Helge Larsen har aktier i Genmab.

]]>https://dev.proinvestor.com/forum/post/9479617https://dev.proinvestor.com/forum/post/9479617Mon, 12 Dec 2022 11:44:22 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Mon, 12 Dec 2022 05:15:25 GMT]]>Genmab præsenterer lovende data for kræfthåb på konference i USA

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/9479622https://dev.proinvestor.com/forum/post/9479622Mon, 12 Dec 2022 05:15:25 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Mon, 12 Dec 2022 04:21:30 GMT]]>Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Ran

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/9479615https://dev.proinvestor.com/forum/post/9479615Mon, 12 Dec 2022 04:21:30 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Sun, 11 Dec 2022 19:03:38 GMT]]>Talquetamab Generates High Response Rate in Hard-to-Treat Multiple Myeloma .

Just a moment...

favicon

(journals.lww.com)

]]>https://dev.proinvestor.com/forum/post/9479616https://dev.proinvestor.com/forum/post/9479616Sun, 11 Dec 2022 19:03:38 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Sun, 11 Dec 2022 12:09:05 GMT]]>Monumen-TAL - I dismantle the ASH/ NEJM Talquetamab study ' First of the ASH 2022 video series

]]>https://dev.proinvestor.com/forum/post/9479619https://dev.proinvestor.com/forum/post/9479619Sun, 11 Dec 2022 12:09:05 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Sun, 11 Dec 2022 09:55:25 GMT]]>ASH 2022: Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Re...

Recorded @ ASH 2022 PressBriefing, December 10/ More Info from ASH @ https://oncoletter.ch

]]>https://dev.proinvestor.com/forum/post/9479610https://dev.proinvestor.com/forum/post/9479610Sun, 11 Dec 2022 09:55:25 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Sun, 11 Dec 2022 09:51:51 GMT]]>Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable

]]>https://dev.proinvestor.com/forum/post/9479611https://dev.proinvestor.com/forum/post/9479611Sun, 11 Dec 2022 09:51:51 GMT<![CDATA[Reply to ASH22-Program for fremlæggelse af data på Genmabs lægemidler on Sun, 11 Dec 2022 09:50:07 GMT]]>Janssen Presents First Data fromMajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma

https://www.janssen.com/janssen-presents-first-data-majestec-2-trial-tecvayli-teclistamab-cqyv-combination-darzalex-faspro

]]>https://dev.proinvestor.com/forum/post/9479608https://dev.proinvestor.com/forum/post/9479608Sun, 11 Dec 2022 09:50:07 GMT